Literature DB >> 27158350

A special subtype of POEMS syndrome: IgG4 subtype.

Miao Zheng1, Pan Zhou1, Kai Zheng2, Li Meng1, Xian Liu1, Mengdi Chu1, Jie Lu3, Lingli Dong4.   

Abstract

Both POEMS syndrome and IgG4 related diseases are uncommon and clinical manifestations have been multifarious and nonspecific. There is still no literature describing the relationships between these two diseases. This study describes a case of a 33-year-old woman with POEMS syndrome, who had high serum IgG4 concentration and monoclonal IgG4 positive plasmacyte tissue infiltration. This is the first available report of the IgG4 subtype of POEMS syndrome. It is found that the best treatment is to find a novel therapy that targets the plasma cells directly.

Entities:  

Keywords:  IgG4 related diseases; POEMS syndrome

Year:  2016        PMID: 27158350      PMCID: PMC4846907     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  26 in total

1.  Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.

Authors:  Y Masaki; L Dong; N Kurose; K Kitagawa; Y Morikawa; M Yamamoto; H Takahashi; Y Shinomura; K Imai; T Saeki; A Azumi; S Nakada; E Sugiyama; S Matsui; T Origuchi; S Nishiyama; I Nishimori; T Nojima; K Yamada; M Kawano; Y Zen; M Kaneko; K Miyazaki; K Tsubota; K Eguchi; K Tomoda; T Sawaki; T Kawanami; M Tanaka; T Fukushima; S Sugai; H Umehara
Journal:  Ann Rheum Dis       Date:  2008-08-13       Impact factor: 19.103

Review 2.  IgG4 disease.

Authors:  Motohisa Yamamoto; Masato Hashimoto; Hiroki Takahashi; Yasuhisa Shinomura
Journal:  J Neuroophthalmol       Date:  2014-12       Impact factor: 3.042

3.  Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia.

Authors:  Yawara Kawano; Tatsuya Nakama; Hiroyuki Hata; En Kimura; Natsue Maruyoshi; Makoto Uchino; Hiroaki Mitsuya
Journal:  J Neurol Sci       Date:  2010-07-31       Impact factor: 3.181

4.  Pentraxin-3 and VEGF in POEMS syndrome: a 2-year longitudinal study.

Authors:  Chiara Briani; Chiara Dalla Torre; Federica Lessi; Tiziana Cavallaro; Marina Scarlato; Sergio Ferrari; Marta Campagnolo; Marta Lucchetta; Ilaria Cabrini; Michela Morbin; Giuseppe Lauria; Fausto Adami; Angelo A Manfredi
Journal:  J Neuroimmunol       Date:  2014-10-05       Impact factor: 3.478

5.  POEMS syndrome: definitions and long-term outcome.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; S Vincent Rajkumar; Terry M Therneau; Dirk R Larson; Philip R Greipp; Thomas E Witzig; Rita Basu; Guillermo A Suarez; Rafael Fonseca; John A Lust; Morie A Gertz
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

6.  Multimodal imaging and clinical characteristics of bone lesions in POEMS syndrome.

Authors:  Xiao-Feng Shi; Shu-Dong Hu; Jun-Min Li; Xian-Fu Luo; Zhang-Biao Long; Yan Zhu; Xiao-Dong Xi
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 7.  POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood Rev       Date:  2007-09-11       Impact factor: 8.250

8.  18F-FDG PET/CT in the evaluation of POEMS syndrome.

Authors:  M A Albertí; S Martinez-Yélamos; A Fernandez; A Vidaller; J A Narváez; L M Cano; C Gamez; J A Martinez-Matos
Journal:  Eur J Radiol       Date:  2009-07-05       Impact factor: 3.528

Review 9.  POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.

Authors:  Angela Dispenzieri
Journal:  Am J Hematol       Date:  2014-02       Impact factor: 10.047

10.  Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis.

Authors:  Marina Scarlato; Stefano Carlo Previtali; Marinella Carpo; Davide Pareyson; Chiara Briani; Roberto Del Bo; Eduardo Nobile-Orazio; Angelo Quattrini; Giacomo Pietro Comi
Journal:  Brain       Date:  2005-06-23       Impact factor: 13.501

View more
  2 in total

Review 1.  IgG4-related disease: what a hematologist needs to know.

Authors:  Luke Y C Chen; Andre Mattman; Michael A Seidman; Mollie N Carruthers
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

Review 2.  Active IgG4-related disease with bone marrow involvement: a report of 2 cases and case-based review.

Authors:  Shiyi Liu; Hui Wang; Tao Su
Journal:  Eur J Med Res       Date:  2022-02-02       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.